Clinical Trial Update: Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 study evaluating a combination of bortezomib, rituximab, and yttrium-90 ibritumomab tiuxetan in relapsed or refractory low-grade, follicular, or mantle …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Mantle Cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Rituxan (rituximab)
• Velcade (bortezomib)
• Zevalin (ibritumomab tiuxetan)

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Lymphoma | Phase 1 | Status: COMPLETED